GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...

The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...

Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...

Hetero and Gilead have partnered to expand access to lenacapavir, a groundbreaking HIV treatment, in 120 low- and ...

The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...

The generic companies that will manufacture and supply Lenacapavir to 120 countries are Dr. Reddy’s, Emcure, Eva Pharma, ...

We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...

Dr Reddy's Laboratories has partnered with Gilead Sciences to manufacture and commercialize the HIV drug Lenacapavir in India ...